Provenance du réseau au premier degré de Henry Ho
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
NanoMab Technology Ltd.
 NanoMab Technology Ltd. Pharmaceuticals: MajorHealth Technology NanoMab Technology Ltd. is a Chinese biopharmaceutical company that focuses on developing radiopharmaceuticals for cancer precision therapies. NanoMab Technology is based in Shanghai, CN and was founded in 2016 by Hong-Hoi Ting and Henry Ho. The private company aims to address the unmet medical needs of cancer patients worldwide by developing a pipeline of theranostics using its proprietary camelid antibody platform. NanoMab has filed an IMPD on NM-01 with the UK Medical Healthcare Products Regulatory Agency and is developing its radio-labelled NM-02 for clinical trials in both imaging and treatment of breast and gastric cancers. The company's third program, NM-03, is a single domain antibody targeting a pan-cancer marker and is in preclinical development as a theranostic.
3
| Private Company | Pharmaceuticals: Major | 3 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Henry Ho via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| RADIOPHARM THERANOSTICS LIMITED | Medical/Nursing Services | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Oxford Vacmedix UK Ltd.
 Oxford Vacmedix UK Ltd. Pharmaceuticals: MajorHealth Technology Oxford Vacmedix UK Ltd. develops vaccines for the prevention of infectious diseases and cancer. The company was founded by Patrick Charles Morrish Baddeley in 2012 and is headquartered in Oxford, the United Kingdom. | Pharmaceuticals: Major | Chief Executive Officer | |
Shanghai Full-Life Technologies Co. Ltd.
 Shanghai Full-Life Technologies Co. Ltd. BiotechnologyHealth Technology Shanghai Full-Life Technologies Co. Ltd. is a Chinese company that focuses on radiopharmaceutical research and development, as well as production and commercialization. The private company's goal is to deliver clinical impact for patients. | Biotechnology | Founder |
Statistiques
Internationale
| Royaume-Uni | 3 |
| Australie | 2 |
| Chine | 2 |
Sectorielle
| Health Technology | 4 |
| Health Services | 2 |
Opérationnelle
| Director/Board Member | 3 |
| Chief Tech/Sci/R&D Officer | 3 |
| Founder | 2 |
| Corporate Officer/Principal | 2 |
| Chief Executive Officer | 1 |
Relations les plus connectées
| Insiders | |
|---|---|
| Hong-Hoi Ting | 4 |
| Gitasha Chand | 2 |
| Levente Meszaros | 2 |
